Abstract
The complement system represents an effective arsenal of innate immunity as well as an interface between innate and adaptive immunity. Activation of the complement system culminates with the assembly of the C5b-9 terminal complement complex on cell membranes, inducing target cell lysis. Translation of this sequence of events into a malignant setting has traditionally afforded C5b-9 a strict antitumoral role, in synergy with antibody-dependent tumor cytolysis. However, in recent decades, a plethora of evidence has revised this view, highlighting the tumor-promoting properties of C5b-9. Sublytic C5b-9 induces cell cycle progression by activating signal transduction pathways (e.g., Gi protein/ phosphatidylinositol 3-kinase (PI3K)/Akt kinase and Ras/Raf1/ERK1) and modulating the activation of cancer-related transcription factors, while shielding malignant cells from apoptosis. C5b-9 also induces Response Gene to Complement (RGC)-32, a gene that contributes to cell cycle regulation by activating the Akt and CDC2 kinases. RGC-32 is expressed by tumor cells and plays a dual role in cancer, functioning as either a tumor promoter by endorsing malignancy initiation, progression, invasion, metastasis, and angiogenesis, or as a tumor suppressor. In this review, we present recent data describing the versatile, multifaceted roles of C5b-9 and its effector, RGC-32, in cancer.
Introduction
Carcinogenesis in human somatic cells involves a series of genetic and epigenetic alterations that culminate in the generation of a malignant tissue fully prepared to elude most anticancer defense strategies. To date, there are seven key alterations in cancerous cells: self-sufficiency in growth signals; insensitivity to growth suppressors; evasion of apoptosis, enabling replicative immortality; sustained angiogenesis; tissue invasion (metastasis) () and the presence of cancer-related inflammation (CRI) (). Essential orchestrators of CRI are the tumor-associated inflammatory cells (macrophages, fibroblasts, T cells and myeloid-derived suppressor cells) and their secreted chemokines and cytokines, along with complement activation within the tumor microenvironment (, ).
The complement system represents an effective arsenal of innate immunity as well as an interface between innate and adaptive immunity. An ancestral instrument in fighting invasive pathogens and efficient clearance of debris, the complement system can be activated by the classical, alternative, or lectin pathway, all of which unite at the level of C3 activation. All three pathways lead to the membrane attack complex formation and to cell lysis. Activation of the terminal complement proteins C5 to C9 generates membrane-inserted complexes C5b-7, C5b-8, and finally C5b-9, the so-called membrane attack complex (MAC) (, ).
Evidence supporting complement activation, in association with C5b-9 deposits during the antitumoral response exists for a variety of human malignancies (). Niculescu et al. provided the first immunohistochemical support for the presence of C5b-9 deposits (along with IgG, C3 and C4 deposits) in a human cancerous tissue, namely breast carcinoma (). Thereafter, numerous studies demonstrated C5b-9 deposition indicating complement activation in human thyroid (), ovarian (), endometrial (), gastric (–), liver (), colon, renal, and lung carcinomas (), as well as in human osteosarcoma (), medulloblastoma (), glioma (, ), and gastrointestinal stromal tumor () tissues. High levels of soluble C5b-9 were also detected in the ascitic fluid of ovarian cancer (). Elevated circulating C9 protein levels have been reported in the serum or plasma of colon () and gastric () adenocarcinoma, oral squamous cell carcinoma () and squamous cell lung cancer () patients.
C5b-9 has been shown to possess antitumoral properties, acting in synergy with monoclonal antibody (mAb)-based immunotherapies, many of which use complement activation and C5b-9 as an effector to kill tumor cells (, ). In this context, the mAb triggers C5b-9 assembly on cells leading to tumor destruction. Nevertheless, in recent decades, a plethora of evidence has brought about a conceptual switch in this paradigm () and exposed the tumor-promoter properties of C5b-9.
Here, we summarize the available data concerning the complex and versatile role of C5b-9, and that of its pivotal effector RGC-32, in cancer.
Effects of Lytic C5b-9 on Tumor Cells
Successful achievement of cell lysis during complement-dependent cytotoxicity (CDC) requires the formation of multiple C5b-9 complexes on the cell surface (). Once malignant Ehrlich ascites cells already bearing C5b-8 complexes are exposed to C9, a rapid and extensive ATP depletion, coupled with leakage of the adenine nucleotides ATP, ADP, and AMP, precedes cell death. Other prelytic events include the loss of mitochondrial membrane potential with consequent defective ATP synthesis and a vigorous Ca2+ influx, which initiate necrotic cell death ().
The morphologic and biochemical changes induced by lytic MAC attack do share some features with those seen in apoptosis (nucleolar changes), although most features correspond more closely to necrotic changes (loss of volume control and defective mitochondria) (, ). The main biochemical changes include Bid cleavage, caspase activation, and activation of extracellular DNases (–). The impact of lytic C5b-9 on the malignant signaling pathways is multifaceted, since CDC has been documented to use several necrotic cell death pathways involving the receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3) and mixed-lineage kinase domain-like protein (MLKL) (), in concert with the effectors JNK and Bid. The RIPK1/RIPK3/MLKL pathway closely resembles TNF-alpha-induced necroptosis ().
Tumor cells have developed complement resistance through C5b-9 removal (), expression of membrane complement-regulatory proteins (mCRPs) and other cell surface-protective molecules, and secretion of soluble complement inhibitors (, ). The ability of a cell to survive an initial complement-mediated membrane attack affords its resistance against future attacks ().
The use of mAb-based immunotherapies that stimulate the destruction of tumor cells by CDC has received a lot of interest (). The quest for optimal efficacy in CDC has incited many research teams. For instance, Diebolder et al. have shown that IgG hexamerization after antigen binding leads to more effective complement activation and fixation, and thus a more potent CDC (). Narrow C5b-8 pores formed without C9 are sufficient for CDC due to efficient antibody-mediated hexamer formation (). By neutralizing mCRP expression on leukemia cells, Mamidi et al. were the first to achieve both enhanced CDC and improved complement-dependent cellular cytotoxicity by monocyte-derived macrophages and macrophages induced by two anti-CD20 antibodies (rituximab and ofatumumab) and one anti-CD52 antibody (alemtuzumab) (). Of late, the miR-200b, miR-200c, and miR-217 microRNAs have been recognized as potential regulators of mortalin as well as CD46 and CD55 expression in leukemia/ lymphoma and have been observed to coordinate the quantity of C5b-9 deposited on target cells ().
Sublytic C5b-9 Induces Tumor Cell Proliferation and Transcriptional Activation in Malignant Cells
Sublytic levels of C5b-9 assembly in the membrane of malignant cells generate several different biological responses: activation of signal transduction pathways, proliferation, and modulation of apoptosis (, ) (Figure 1).
Figure 1
One of the first investigations of C5b-9 looked at the generation of signal messengers in Ehrlich carcinoma cells by the sublytic terminal complement complexes (TCC) C5b-9, C5b-8, and C5b-7 and identified the signal messengers involved in eliminating TCC from the cell surface (). Exposure of Ehrlich carcinoma cells to C5b-9 caused an increase in cytosolic Ca2+. In addition, sublytic C5b-9 and C5b-8 substantially increased PKC activity, and C5b-8 and C5b-7 induced an increase in cAMP (). In another report, sublytic C5b-9 assembly in lymphoblastoid human B cells stimulated the production of diacylglycerol (DAG) and ceramide (mediators of inflammation and tissue repair), along with PKC activation (). Rapid elimination of TCC from the membrane surface was inhibited by pretreatment with pertussis toxin, suggesting the involvement of a Gi protein ().
One of the pioneer studies on sublytic C5b-9-induced tumor cell proliferation through mitotic signaling () demonstrated that a significant increase in DNA synthesis over the C5b6 level is induced by C5b-9 in the human lymphoblastoid B cell line JY 25. This effect (but not the basal DNA synthesis activity) could be abrogated by pertussis toxin pretreatment, indicating the involvement of activated Gi proteins in DNA synthesis induced by C5b-9 in tumor cells () (Figure 1). Pretreatment of cells with PD98059 (specific inhibitor of MEK1 activation) was also effective in abolishing C5b-9-induced DNA synthesis (). Both ERK1, a member of a potentially pro-oncogenic signal transduction pathway, and PI3K contribute to the transmission of downstream cellular effects prompted by sublytic C5b-9 (, , ). Indeed, as shown by Pilzer et al., C5b-9 deposition on the K562 leukemic cell membrane activates PKC and ERK protein kinases (), which then induce the relocation of the mitochondrial chaperone mortalin from the mitochondria to the plasma membrane, where mortalin escorts exo-vesiculated C5b-9 complexes (). Co-localization of mortalin and C5b-9 in distinct puncta at the leukemic cell plasma membrane region has also been well-documented (). Mortalin is overexpressed in a multitude of malignancies, and a high level of circulating mortalin was recently demonstrated to correlate with high mortality in colorectal cancer patients (). Mortalin supports the process of carcinogenesis by suppressing pathway-mediated growth-inhibitory signaling, inactivating tumor suppressor p53, and activating epithelial-to-mesenchymal transition (EMT) signaling (). In addition, Rozenberg et al. has found that HSP90 binds to mortalin and protects cells from complement-mediated cytotoxicity by inhibiting, together with mortalin, C5b-9 assembly on the plasma membrane ().
Among the signal transduction networks regulating cancer progression that have been found to function downstream of sublytic C5b-9 are p38/MAPK/JNK1 and JAK1/STAT3 (, ). Cellular proliferation induced by membrane-inserted sublytic C5b-9 relies on the activation of the Gi protein/PI3K/Akt kinase and Ras/Raf-1/ERK1 pathways and regulation of cell cycle-specific genes and proto-oncogenes (, ) (Figure 1).
Of note, activation of activating protein 1 (AP-1) transcription factor has also been documented following C5b-9 treatment of lymphoblastoid B-cell lines (). Consistent with this finding, stimulation with C5b-9 enhances the expression of the oncogenic proteins c-jun, JunD, and c-fos (). AP-1 functions are dependent on the specific Fos and Jun subunits contributing to AP-1 dimers (). AP-1 activity is crucial to oncogenesis, and there is evidence that it has an ambivalent role: while it can act as a tumor promoter in some cancer types, it also represses tumor formation in others (). NF-κB is another major transcription factor known to be activated by sublytic C5b-9 (, , ). Sublytic C5b-9–induced, NF-κB–regulated proteins may further enhance cell survival () (Figure 1).
In smooth muscle cells (SMC), sublytic assault by MAC stimulates release of insulin-like growth factor-1 (), whereas in glomerular epithelial cells it causes transactivation of the receptors for epidermal growth factor (EGF), human epidermal growth factor 2/Neu, fibroblast growth factor, and hepatocyte growth factor, all vital growth factors during tumor development (). CT26 colon carcinoma cells exposed to sublytic C5b-9 exhibit significant changes in genes involved in Ca2+ and G-protein signal transduction, early response transcription factors (EGR1, EGR2) and four genes encoding proteins with extracellular localization: AREG, CXCL1, MMP3, and MMP13 (). Network analysis has suggested an important role for the EGF receptor as the main canonical signaling cascade in the response to sublytic C5b-9 in the colon carcinoma cells (). This connection is very pertinent to carcinogenesis, since alterations in EGF receptor signaling are common events in several human cancers ().
Non-lethal C5b-9 activates cell cycle by directly influencing major cell cycle regulators: in aortic SMC, sublytic C5b-9 increases the activity of the cyclin-dependent kinases CDK4 and CDK2, whereas in endothelial cells it increases the levels of cell division cycle protein 2 (CDC2), cyclin D1, and proliferating cell nuclear antigen (PCNA) ().
Sublytic C5b-9 Protects Tumor Cells From Apoptosis
Sublytic complement-induced protection against TNF-α-mediated apoptosis accompanies the induction of the anti-apoptotic proteins Bcl-2 and Bcl-xL, along with suppressing the TNF-α-induced decrease in the amount of Bcl-2 and Bcl-xL (, ). The anti-apoptotic effects of sublytic C5b-9 encompass events such as activation of NF-kB and inhibition of caspase-8 activation (, , ). Fascinating insight into the relationship of microvesicles to apoptosis has been provided by the work of Stratton et al. in prostate cancer cells (). Sublytic C5b-9 deposition is among the positive signals that result in a high Ca2+ cellular influx and membrane depolarization; stimulation of microvesicle release then ensures shedding of excess intracellular calcium and export of damaging agents such as deposited C5b-9 and caspase-3. This circuit provides cells with an effective mechanism to thwart apoptosis ().
It should be noted, however, that data also exist in support of the ability of sublytic C5b-9 to activate various molecules that potentially contribute to programed cellular death. In lung epithelial cells, MAC insertion has been observed to induce Ca2+ influx, leading to mitochondrial overload and loss of mitochondrial transmembrane potential. These changes prompt NLPR3 inflammasome activation, as well as IL-1β production, cytoplasmatic cytochrome c release and caspase activation (). A similar chain of events has been described in macrophages in which “bystander” deposition of MAC on the plasma membranes of phagocytic macrophages incite NLRP3 inflammasome and caspase-1 activation, together with IL-1β and IL-18 release (). Bystander C5b-9 deposition has also been found to modulate T-cell polarization and leucocyte recruitment to the phagocytic sites (). Despite the analogy with apoptosis, the involvement of NLRP3 inflammasomes, caspase-1, IL-1β, and IL-18 rather evokes another form of programmed cellular death, pyroptosis (67). While activation of pyroptosis provides powerful ammunition against many types of cancers, other researchers have reported that the NLRP3 inflammasome and IL-1β pathway promote cancer progression in animal and human breast cancer models (68) and asbestos-induced malignant mesothelioma (69). In addition, sublytic C5b-9 has been shown to interact with effectors of TNFα-induced necroptosis, yet another type of programmed cell death: exposure of human erythroleukemia K562 cells to sublytic C5b-9 causes the activation of RIPK1, RIPK3, and MLKL, co-localization of RIPK3 with RIPK1 in the cytoplasm and co-localization of RIPK3 and MLKL with C5b-9 at the plasma membrane (). The meaning of the association between C5b-9 and necroptotic effectors has many nuances: RIPK3 and MLKL are in fact seen as putative tumor suppressors (70), but in vitro work in breast cancer cells has recently highlighted the contributions of the necroptotic genes RIPK1, RIPK3, and MLKL in promoting anchorage-independent tumor growth and mediating tumor cell resistance to radiation (71).
C5b-9 and Angiogenesis
Although initiated by cellular destruction and hypoxia, the propagation of the vascular network in a malignant environment is sustained by upregulation of pro-angiogenic factors (e.g. vascular endothelial growth factor [VEGF], TGF-α, TGF-β, TNF-α, EGF, fibroblast growth factor [FGF]) and downregulation of negative angiogenic regulators (IL-10, IL-12, angiopoietin-2, angiotensin) (72).
Accelerated C5b-9 deposition, accompanied by VEGF, β-FGF, and TGF-β2 release is seen during laser-induced choroidal neovascularization in age-related macular degeneration in CD59-deficient mice (73). Likewise, exposure of retinal pigment epithelium cells to oxidative stress has been found to induce sublytic C5b-9 activation, triggering VEGF secretion via the Src and Ras-Erk pathways (74).
The effects of C5b-9 were later corroborated in cancer cells. In an osteosarcoma epithelial cell line, sublytic C5b-9 activation (via the alternative pathway) instigated production of angiogenic growth factors FGF1 and VEGF-A via the ERK signaling pathway ().
RGC-32 and Cancer
The RGC-32 gene was first cloned from rat oligodendrocytes via differential display by Badea and coworkers, in their quest to identify the genes differentially expressed in response to sublytic complement activation (75, 76). RGC-32 fundamentally regulates cellular processes such as the cell cycle, differentiation, wound healing and tumorigenesis (75, 77). It directly binds to cyclin-dependent kinase CDC2 and Akt and stimulates their kinase activity (75, 78).
Various studies have described an aberrant RGC-32 mRNA expression in human cancers: up-regulation in colon (79, 80), ovarian (81, 82), breast (79, 83, 84) and prostate (79) cancers and lymphomas (85, 86) and downregulation in glioblastomas (87), astrocytomas (88), adrenocortical carcinomas (89), and multiple myelomas (90).
We have originally demonstrated a role for RGC-32 deregulation in colon adenocarcinoma, showing that the intensity of RGC-32 immunohistochemical staining corresponded to the increase in the TNM staging of the adenocarcinomas (77). Later, the expression of RGC-32 was shown to be up-regulated in pancreatic cancer tissues and to correlate with TNM stages (91).
Using a gene array and SW480 colon adenocarcinoma cells, we have identified groups of genes that are significantly changed by RGC-32 silencing (77), including genes implicated in chromatin assembly, cell cycle, and RNA processing. We have observed increased lysine acetylation at multiple sites on histones H2B, H3, and H4, and lessened expression of the histone deacetylase SIRT1 upon silencing of RGC-32 expression in SW480 cells (77) (Figure 2). Moreover, an absence of RGC-32 expression induces DNA synthesis and mitosis in colon cancer cells (77). Correspondingly, overexpression of RGC-32 in several cancer cell lines has been shown to delay G2/M cell cycle progression (88).
Figure 2
On the other hand, others have reported that RGC-32 promotes malignant cell proliferation in the colon adenocarcinoma cell line SW480 (80) and in lung adenocarcinoma LTE cells (92). Overexpression of RGC-32 protein in Epstein Barr virus (EBV)-immortalized B cells has been found to disrupt the G2/M checkpoint via CDK1 activation, and RGC-32 has been shown to be indispensable for the growth and survival of lymphoblastoid B cells (86, 93) (Figure 2).
The cooperation of RGC-32 with SMAD3, as TGF-β downstream effectors, in the regulation of EMT seen in renal tubular cells (95) indicates a possible involvement of RGC-32 in invasion and metastasis. RGC-32 was shown to influence expression of vimentin, cadherin, and the transcription factors Snail and Slug in pancreatic and colon cancer lines (80, 91) (Figure 2). Also, excessive RGC-32 expression in a colon cancer cell line prompts cytoskeleton reorganization and cell migration (96). Similarly, RGC-32 has been demonstrated to induce EMT and to promote cancer cell migration and invasion in lung adenocarcinoma cells via decreases in the protein level and activity of the matrix metalloproteinases MMP-2 and MMP-9 (92, 97).
Research focusing on the effects of RGC-32 in animal cancer models has yielded contrasting data. Colon cancer tumors lacking RGC-32 that were implanted into nude mice were observed to have a lower growth rate and significantly smaller tumor volumes than did the tumors with intact RGC-32 expression (80). In striking contrast, inoculating RGC-32 into colon cancer tumors placed subcutaneously in mice resulted in a significant tumor growth suppression and decline in angiogenesis (94) (Figure 2).
The thesis of RGC-32 as a functional dyad (tumor suppressor/ promoter) accounts for its contradictory behavior during cancerogenesis: the protein acts in a pleiotropic manner in distinct malignant settings, dependent on the cellular lineage and on the various ligands. For instance, RGC-32 exerts a tumor-suppressive effect in lung adenocarcinomas with wild-type TP53, but a tumor-promoting effect in the tumors carrying TP53 mutations (98). Targeting RGC-32 should be done in conjunction with the role played in specific tumors as well as by using biomarkers that can predict the efficacy of RGC-32 inhibitors in cancer patients. Future studies are needed in order to find effective RGC-32-based drugs.
Conclusions
Considering all the available data, the role of C5b-9 in cancer is indisputably versatile: while it is lethal to tumor cells in a lytic context, when C5b-9 becomes activated to a sublytic level, it instead stimulates tumor growth through several mechanisms. Counteracting these tumor-promoting traits of C5b-9 by therapeutically surmounting CDC resistance in cancer cells and potentiating the antitumoral actions of C5b-9 (and therefore the efficacy of mAb-based immunotherapy) constitutes the next major direction in the field of immuno-oncology.
Statements
Author contributions
HR designed the study. SV, AT, VR, and HR wrote the manuscript. All authors approved the manuscript.
Funding
This work was supported in part by a Veterans Administration Merit Award I01BX001458 (to HR) and by an RO1 NS42011 grant (to HR).
Acknowledgments
We thank Dr. Deborah McClellan for editing this manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- AP-1
activator protein 1
- CDC
complement-dependent cytotoxicity
- CDK1
cyclin–dependent kinase 1
- CyB1
cyclin B1
- CyE
cyclin E
- EBV
Epstein-Barr virus
- EGF
epidermal growth factor
- ERK1
extracellular signal-regulated kinase 1
- FGF2
fibroblast growth factor 2
- HIF-1α
hypoxia inducible factor 1 alpha
- IKKα
inhibitor of nuclear factor kappa-B kinase subunit alpha
- JAK1
Janus kinase 1
- MAC
membrane attack complex
- MEK1/2
mitogen activated protein kinase kinase 1
- mTORC2
mammalian target of rapamycin complex 2
- NF-κB
nuclear factor kappa-light-chain-enhancer of activated B cells
- PLK1
polo-like kinase 1
- RGC-32
response gene to complement 32
- RIPK
receptor-interacting protein kinase
- TCC
terminal complement complex
- VEGF
vascular endothelial growth factor
- STAT3
signal transducer and activator of transcription 3.
Abbreviations
References
1.
HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. 10.1016/j.cell.2011.02.013
2.
BalkwillFRMantovaniA. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. (2012) 22:33–40. 10.1016/j.semcancer.2011.12.005
3.
NiculescuFRusHGReteganMVlaicuR. Persistent complement activation on tumor cells in breast cancer. Am J Pathol. (1992)140:1039–43.
4.
ShinMLRusHGNiculescuFI. Membrane attack by complement: assembly and biology of terminal complement complexes. In: LeeAG, editor. Biomembranes: A Multi-Volume Treatise. Volume 4. JAI.Greenwich, CT: JAI Press (1996). p. 123–49.
5.
TeglaCACudriciCPatelSTrippeRIIIRusVNiculescuFet al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. (2011) 51:45–60. 10.1007/s12026-011-8239-5
6.
VlaicuSITeglaCACudriciCDDanoffJMadaniHSugarmanAet al. Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res. (2013) 56:109–21. 10.1007/s12026-012-8381-8
7.
YamakawaMYamadaKTsugeTOhruiHOgataTDobashiMet al. Protection of thyroid cancer cells by complement-regulatory factors. Cancer. (1994) 73:2808–17.
8.
ChoMSVasquezHGRupaimooleRPradeepSWuSZandBet al. Autocrine effects of tumor-derived complement. Cell Rep. (2014) 6:1085–95. 10.1016/j.celrep.2014.02.014
9.
ChenJYangWJSunHJYangXWuYZ. C5b-9 Staining Correlates With Clinical and Tumor Stage in Gastric Adenocarcinoma. Appl Immunohistochem Mol Morphol. (2016) 24:470–5. 10.1097/PAI.0000000000000218
10.
InoueTYamakawaMTakahashiT. Expression of complement regulating factors in gastric cancer cells. Mol Pathol. (2002) 55:193–9. 10.1136/mp.55.3.193
11.
NiehansGACherwitzDLStaleyNAKnappDJDalmassoAP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol. (1996) 149:129–42.
12.
JeonHHanSRLeeSParkSJKimJHYooSMet al. Activation of the complement system in an osteosarcoma cell line promotes angiogenesis through enhanced production of growth factors. Sci Rep. (2018) 8:5415. 10.1038/s41598-018-23851-z
13.
BouwensTATrouwLAVeerhuisRDirvenCMLamfersMLAl-KhawajaH. Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. J Neuroimmunol. (2015) 278:271–6. 10.1016/j.jneuroim.2014.11.016
14.
BjorgeLHakulinenJVintermyrOKJarvaHJensenTSIversenOEet al. Ascitic complement system in ovarian cancer. Br J Cancer. (2005) 92:895–905. 10.1038/sj.bjc.6602334
15.
MurakoshiYHondaKSasazukiSOnoMNegishiAMatsubaraJet al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci. (2011) 102:630–8. 10.1111/j.1349-7006.2010.01818.x
16.
ChongPKLeeHLohMCChoongLYLinQSoJBet al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics. (2010) 10:3210–21. 10.1002/pmic.201000127
17.
GallenkampJSpanierGWorleEEnglbrechtMKirschfinkMGreslechnerRet al. A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma. Oncotarget. (2018) 9:3001–13. 10.18632/oncotarget.22963
18.
NarayanasamyAAhnJMSungHJKongDHHaKSLeeSYet al. Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteomics. (2011) 74:2948–58. 10.1016/j.jprot.2011.07.019
19.
MacorPCapollaSTedescoF. Complement as a biological tool to control tumor growth. Front Immunol. (2018) 9:2203. 10.3389/fimmu.2018.02203
20.
TaylorRPLindorferMA. The role of complement in mAb-based therapies of cancer. Methods. (2014) 65:18–27. 10.1016/j.ymeth.2013.07.027
21.
ReisESMastellosDCRicklinDMantovaniALambrisJD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol. (2018) 18:5–18. 10.1038/nri.2017.97
22.
KoskiCLRammLEHammerCHMayerMMShinML. Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci USA. (1983). 80:3816–20.
23.
PapadimitriouJCRammLEDrachenbergCBTrumpBFShinML. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J Immunol. (1991) 147:212–7.
24.
PapadimitriouJCDrachenbergCBShinMLTrumpBF. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. Virchows Arch. (1994) 424:677–85.
25.
CraggMSHowattWJBloodworthLAndersonVAMorganBPGlennieMJ. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ. (2000) 7:48–58. 10.1038/sj.cdd.4400627
26.
GanczDFishelsonZ. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol. (2009) 46:2794–800. 10.1016/j.molimm.2009.05.009
27.
ZiporenLDoninNShmushkovichTGrossAFishelsonZ. Programmed necrotic cell death induced by complement involves a Bid-dependent pathway. J Immunol. (2009) 182:515–21. 10.4049/jimmunol.182.1.515
28.
LusthausMMazkerethNDoninNFishelsonZ. Receptor-interacting protein kinases 1 and 3, and mixed lineage kinase domain-like protein are activated by sublytic complement and participate in complement-dependent cytotoxicity. Front Immunol. (2018) 9:306. 10.3389/fimmu.2018.00306
29.
CarneyDFKoskiCLShinML. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol. (1985)134:1804–9.
30.
Bohana-KashtanOZiporenLDoninNKrausSFishelsonZ. Cell signals transduced by complement. Mol Immunol. (2004) 41:583–97. 10.1016/j.molimm.2004.04.007
31.
DoninNJurianzKZiporenLSchultzSKirschfinkMFishelsonZ. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. J Clin Exp Immunol. (2003) 131:254–63. 10.1046/j.1365-2249.2003.02066.x
32.
FishelsonZDoninNZellSSchultzSKirschfinkM. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol immunol. (2003) 40:109–23. 10.1016/S0161-5890(03)00112-3
33.
DiebolderCABeurskensFJde JongRNKoningRIStrumaneKLindorferMAet al. Complement is activated by IgG hexamers assembled at the cell surface. Science. (2014) 343:1260–3. 10.1126/science.1248943
34.
TaylorRPLindorferMACookEMBeurskensFJSchuurmanJParrenPet al. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. Clin Immunol. (2017) 181:24–8. 10.1016/j.clim.2017.05.016
35.
MamidiSHoneSTeufelCSellnerLZenzTKirschfinkM. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology. (2015) 4:e979688. 10.4161/2162402X.2014.979688
36.
HillmanYMazkerethNFarberovLShomronNFishelsonZ. Regulation of complement-dependent cytotoxicity by microRNAs miR-200b, miR-200c, and miR-217. J Immunol. (2016) 196:5156–65. 10.4049/jimmunol.1502701
37.
RusHGNiculescuFIShinML. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev. (2001) 180:49–55. 10.1034/j.1600-065X.2001.1800104.x
38.
NiculescuFRusHShinML. Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J Biol Chem. (1994) 269:4417–23.
39.
FosbrinkMNiculescuFRusH. The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res. (2005) 31:37–46. 10.1385/IR:31:1:37
40.
NiculescuFRusHvan BiesenTShinML. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J Immunol. (1997) 158:4405–12.
41.
NiculescuFSoaneLBadeaTShinMRusH. Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology. (1999) 42:187–93. 10.1016/S0162-3109(99)00014-4
42.
Jane-witDSurovtsevaYVQinLLiGLiuRClarkPet al. Complement membrane attack complexes activate noncanonical NF-kappaB by forming an Akt+ NIK+ signalosome on Rab5+ endosomes. Proc Natl Acad Sci USA. (2015) 112:9686–91. 10.1073/pnas.1503535112
43.
StrattonDMooreCAntwi-BaffourSLangeSInalJ. Microvesicles released constitutively from prostate cancer cells differ biochemically and functionally to stimulated microvesicles released through sublytic C5b-9. Biochem Biophys Res Commun. (2015) 460:589–95. 10.1016/j.bbrc.2015.03.074
44.
CarneyDFLangTJShinML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol. (1990) 145:623–9.
45.
NiculescuFRusHShinSLangTShinML. Generation of diacylglycerol and ceramide during homologous complement activation. J Immunol. (1993) 150:214–24.
46.
NiculescuFBadeaTRusH. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis. (1999) 142:47–56. 10.1016/S0021-9150(98)00185-3
47.
NiculescuFRusH. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res. (2001) 24:191–9. 10.1385/IR:24:2:191
48.
PilzerDFishelsonZ. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int Immunol. (2005) 17:1239–48. 10.1093/intimm/dxh300
49.
MazkerethNRoccaFSchubertJRGeislerCHillmanYEgnerAet al. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane. Immunobiology. (2016) 221:1395–406. 10.1016/j.imbio.2016.07.005
50.
JubranRKocsisJGaramNMalatiEGombosTBarabasLet al. Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: risk indicators in colorectal cancer. Int J Cancer. (2017) 141:2329–35. 10.1002/ijc.30918
51.
YunCOBhargavaPNaYLeeJSRyuJKaulSCet al. Relevance of mortalin to cancer cell stemness and cancer therapy. Sci Rep. (2017) 7:42016. 10.1038/srep42016
52.
RozenbergPZiporenLGanczDSaar-RayMFishelsonZ. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9. Cell Death Dis. (2018) 9:150. 10.1038/s41419-017-0240-z
53.
RusHGNiculescuFShinML. Sublytic complement attack induces cell cycle in oligodendrocytes. J Immunol. (1996) 156:4892–900.
54.
GazonHBarbeauBMesnardJMPeloponeseJMJr. Hijacking of the AP-1 Signaling pathway during development of ATL. Front Microbiol. (2017) 8:2686. 10.3389/fmicb.2017.02686
55.
ViedtCHanschGMBrandesRPKublerWKreuzerJ. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. Faseb J. (2000) 14:2370–2. 10.1096/fj.00-0468fje
56.
GanczDLusthausMFishelsonZ. A role for the NF-kappaB pathway in cell protection from complement-dependent cytotoxicity. J Immunol. (2012) 189:860–6. 10.4049/jimmunol.1103451
57.
ZwakaTPTorzewskiJHoeflichADejosezMKaiserSHombachVet al. The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. Faseb J. (2003) 17:1346–8. 10.1096/fj.02-0814fje
58.
CybulskyAVTakanoTPapillonJMcTavishAJ. Complement C5b-9 induces receptor tyrosine kinase transactivation in glomerular epithelial cells. Am J Pathol. (1999) 155:1701–11. 10.1016/S0002-9440(10)65485-5
59.
TownerLDWheatRAHughesTRMorganBP. Complement membrane attack and tumorigenesis: a systems biology approach. J Biol Chem. (2016) 291:14927–38. 10.1074/jbc.M115.708446
60.
SigismundSAvanzatoDLanzettiL. Emerging functions of the EGFR in cancer. Mol Oncol. (2018) 12:3–20. 10.1002/1878-0261.12155
61.
LiuLLiWLiZKirschfinkM. Sublytic complement protects prostate cancer cells from tumour necrosis factor-alpha-induced cell death. Clin Exp Immunol. (2012) 169:100–8. 10.1111/j.1365-2249.2012.04596.x
62.
SoaneLRusHNiculescuFShinML. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol. (1999) 163:6132–8.
63.
CudriciCNiculescuFJensenTZafranskaiaEFosbrinkMRusVet al. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol. (2006) 176:3173–80. 10.4049/jimmunol.176.5.3173
64.
SoaneLChoHJNiculescuFRusHShinML. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol. (2001) 167:2305–11. 10.4049/jimmunol.167.4.2305
65.
TriantafilouKHughesTRTriantafilouMMorganBP. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci. (2013) 126:2903–13. 10.1242/jcs.124388
66.
SureshRChandrasekaranPSutterwalaFSMosserDM. Complement-mediated ‘bystander' damage initiates host NLRP3 inflammasome activation. J Cell Sci. (2016) 129:1928–39. 10.1242/jcs.179291
67.
KolbJPOguinTHIIIOberstAMartinezJ. Programmed cell death and inflammation: winter is coming. Trends Immunol. (2017) 38:705–18. 10.1016/j.it.2017.06.009
68.
GuoBFuSZhangJLiuBLiZ. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep. (2016) 6:36107. 10.1038/srep36107
69.
KadariyaYMengesCWTalarchekJCaiKQKlein-SzantoAJPietrofesaRAet al. Inflammation-Related IL1beta/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. Cancer Prev Res. (2016) 9:406–14. 10.1158/1940-6207.CAPR-15-0347
70.
KryskoOAaesTLKaganVED'HerdeKBachertCLeybaertLet al. Necroptotic cell death in anti-cancer therapy. Immunol Rev. (2017) 280:207–19. 10.1111/imr.12583
71.
LiuXZhouMMeiLRuanJHuQPengJet al. Key roles of necroptotic factors in promoting tumor growth. Oncotarget. (2016) 7:22219–33. 10.18632/oncotarget.7924
72.
PragerGWPoettlerM. Angiogenesis in cancer. Basic mechanisms and therapeutic advances. Hamostaseologie. (2012) 32:105–14. 10.5482/ha-1163
73.
BoraNSKaliappanSJhaPXuQSivasankarBHarrisCLet al. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol. (2007) 178:1783–90. 10.4049/jimmunol.178.3.1783
74.
KunchithapauthamKRohrerB. Sublytic Membrane-Attack-Complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers. J Biol Chem. (2011) 286:23717–24. 10.1074/jbc.M110.214593
75.
BadeaTNiculescuFSoaneLFosbrinkMSoranaHRusVet al. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem. (2002) 277:502–8. 10.1074/jbc.M109354200
76.
BadeaTCNiculescuFISoaneLShinMLRusH. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem. (1998) 273:26977–81. 10.1074/jbc.273.41.26977
77.
VlaicuSITeglaCACudriciCDFosbrinkMNguyenVAzimzadehPet al. Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol. (2010) 88:67–76. 10.1016/j.yexmp.2009.10.010
78.
FosbrinkMCudriciCTeglaCASoloviovaKItoTVlaicuSet al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp Mol Pathol. (2009) 86:87–94. 10.1016/j.yexmp.2008.12.005
79.
FosbrinkMCudriciCNiculescuFBadeaTCDavidSShamsuddinAet al. Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol. (2005) 78:116–22. 10.1016/j.yexmp.2004.11.001
80.
WangXYLiSNZhuHFHuZYZhongYGuCSet al. RGC32 induces epithelial-mesenchymal transition by activating the Smad/Sip1 signaling pathway in CRC. Sci Rep. (2017) 7:46078. 10.1038/srep46078
81.
ChoHLimBJKangESChoiJSKimJH. Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. Tohoku J Exp Med. (2009) 218:129–39. 10.1620/tjem.218.129
82.
DonningerHBonomeTRadonovichMPise-MasisonCABradyJShihJHet al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. (2004) 23:8065–77. 10.1038/sj.onc.1207959
83.
Eskandari-NasabEHashemiMRafighdoostF. Promoter Methylation and mRNA expression of response gene to complement 32 in breast carcinoma. J Cancer Epidemiol. (2016) 2016:7680523. 10.1155/2016/7680523
84.
KangYSiegelPMShuWDrobnjakMKakonenSMCordon-CardoCet al. A multigenic program mediating breast cancer metastasis to bone. Cancer cell. (2003) 3:537–49. 10.1016/S1535-6108(03)00132-6
85.
HahnA. Differentielle Genexpression der Gene APR-1, B56, RGC32 und SIAT-8A bei kutanen T-Zell-Lymphomen.Dissertation, Heidelberg: Ruprecht-Karls-Universität Heidelberg Fakultät für Klinische Medizin Mannheim, (2006).
86.
SchlickS. Investigating the role of RGC-32 in cell cycle disruption by EBV EBNA 3C.Dissertation, Sussex: School of Life Sciences, University of Sussex, (2010).
87.
BredelMBredelCJuricDDuranGEYuRXHarshGRet al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. (2006) 24:274–87. 10.1200/JCO.2005.02.9405
88.
SaigusaKImotoITanikawaCAoyagiMOhnoKNakamuraYet al. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene. (2007) 26:1110–21. 10.1038/sj.onc.1210148
89.
DemeureMJCoanKEGrantCSKomorowskiRAStephanESinariSet al. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery. (2013) 154:1405–16; discussion 16. 10.1016/j.surg.2013.06.058
90.
ZhanFHuangYCollaSStewartJPHanamuraIGuptaSet al. The molecular classification of multiple myeloma. Blood. (2006) 108:2020–8. 10.1182/blood-2005-11-013458
91.
ZhuLQinHLiPYXuSNPangHFZhaoHZet al. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res. (2012) 31:29. 10.1186/1756-9966-31-29
92.
XuRShangCZhaoJHanYLiuJChenKet al. Knockdown of response gene to complement 32 (RGC32) induces apoptosis and inhibits cell growth, migration, and invasion in human lung cancer cells. Mol Cell Biochem. (2014) 394:109–18. 10.1007/s11010-014-2086-3
93.
SchlickSNWoodCDGunnellAWebbHMKhasnisSSchepersAet al. Upregulation of the cell-cycle regulator RGC-32 in Epstein-Barr virus-immortalized cells. PLoS ONE. (2011) 6:e28638. 10.1371/journal.pone.0028638
94.
AnXJinYGuoHFooSYCullyBLWuJet al. Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor. Circulation. (2009) 120:617–27. 10.1161/CIRCULATIONAHA.108.841502
95.
GuoXJosePAChenSY. Response gene to complement 32 interacts with Smad3 to promote epithelial-mesenchymal transition of human renal tubular cells. Am J Physiol. (2011) 300:C1415–21. 10.1152/ajpcell.00204.2010
96.
TianJXuCYangMHLiZG. [Overexpression of response gene to complement-32 promotes cytoskeleton reorganization in SW480 cell line]. Nan Fang Yi Ke Da Xue Xue Bao. (2011) 31:1179–82.
97.
SunQYaoXNingYZhangWZhouGDongY. Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-kappaB signaling pathway. Tumour Biol. (2013) 34:2995–3002. 10.1007/s13277-013-0864-2
98.
KimDSLeeJYLeeSMChoiJEChoSParkJY. Promoter methylation of the RGC32 gene in nonsmall cell lung cancer. Cancer. (2011) 117:590–6. 10.1002/cncr.25451
Summary
Keywords
C5b-9, cancer, RGC-32, cell proliferation, apoptosis
Citation
Vlaicu SI, Tatomir A, Rus V and Rus H (2019) Role of C5b-9 and RGC-32 in Cancer. Front. Immunol. 10:1054. doi: 10.3389/fimmu.2019.01054
Received
30 November 2018
Accepted
24 April 2019
Published
09 May 2019
Volume
10 - 2019
Edited by
Trent M. Woodruff, University of Queensland, Australia
Reviewed by
Zvi Fishelson, Tel Aviv University, Israel; Jun Yan, University of Louisville, United States
Updates
Copyright
© 2019 Vlaicu, Tatomir, Rus and Rus.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Horea Rus hrus@umaryland.edu
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.